30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Proportion of Patients who Complete 2 Weeks of Intervention
Timeframe: Week 2
Proportion of Patients who Tolerate Each Full 15-Minute Session
Timeframe: Week 2
Incidence of Severe Bradycardia following taVNS Use
Timeframe: Up to Week 2
Incidence of Severe Tachycardia following taVNS Use
Timeframe: Up to Week 2
Incidence of Syncope following taVNS Use
Timeframe: Up to Week 2